Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Invion ( (AU:IVX) ) just unveiled an update.
Invion Limited announced a fully underwritten, non-renounceable entitlement offer to raise approximately $1 million. This offer, managed by Blue Ocean Equities Pty Ltd, provides eligible shareholders with new options and aims to strengthen Invion’s financial position, potentially enhancing its market presence in the life-science sector.
More about Invion
Invion is a life-science company focused on the research and development of Photosoft™ technology for treating various cancers, atherosclerosis, and infectious diseases. It holds exclusive rights in Australia, New Zealand, and parts of Asia Pacific for cancer indications and has expanded its rights to the United States, Canada, and Hong Kong for infectious diseases. Invion is listed on the ASX.
YTD Price Performance: -55.36%
Average Trading Volume: 101,227
Technical Sentiment Signal: Sell
Current Market Cap: A$10.59M
See more data about IVX stock on TipRanks’ Stock Analysis page.